A Pharma Company at Throwaway Valuations
This company was once widely popular on Twitter in early 2025.
Now, the stock is dead. The lack of movement would be so huge and would throw out low-patience investors for sure!
Looking at the numbers closely from FY21 to FY26, revenue remained flattish, with FY24 and FY25 witnessing a revenue decline. FY21 and FY22 elevated the revenue base because of unprecedented demand for COVID-related molecules. Post-COVID, due to the API price decline and shifts in the product mix, the FY24 and FY25 revenues look subdued.









